XERS

AI Memo

Xeris Biopharma

As of 2026-09-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

H2 Recorlev execution and FY2026 guidance delivery • 2026-12-31

Base target: $10 / p=50% prob

Biggest risk

The thesis remains dependent on continued Recorlev momentum and execution of the XP-8121 plan. Gvoke declined 4% year over year, SG&A rose 37%, R&D rose 32%, and coverage is limited. Analyst revisions and verified post-earnings market reaction are unavailable.

Invalidation

Break below $7 or thesis failure.

What would change my mind?

Commercial execution is the strongest supported upside driver: Recorlev growth, improving gross margin, tighter FY2026 guidance, and potential XP-8121 development progress could support a rerating.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-02

Base target

$10

p=50%

Bull target

$13

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Recent officer open-market sales
XP-8121 Phase 3 initiation
KEVEYIS intellectual-property durability

BearKey bullets

Gvoke revenue declined 4% year over year in Q2 2026.
Higher commercial and R&D spending could pressure earnings and cash generation.
Low analyst coverage, unavailable revision data, and loose peer comparability reduce conviction.

WatchKey bullets

H2 Recorlev execution and FY2026 guidance delivery

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $10 (p=50%)

Target spread vs base: +27% / -37%

Scenario probabilities

Bull Target: $13 (p=25%)Base Target: $10 (p=50%)Bear Target: $7 (p=25%)

Commentary

Qualitative news tone is constructive after the Q2 release, driven by revenue growth, Recorlev momentum, tighter guidance, and the KEVEYIS patent allowance. Verified post-release price reaction, analyst revisions, options data, short interest, employee sentiment, and social coverage are unavailable; missing data is not treated as positive evidence. The low-coverage and loose-peer setup supports cautious monitoring rather than a high-conviction thesis.

As of 2026-09-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Commercial execution is the strongest supported upside driver: Recorlev growth, improving gross margin, tighter FY2026 guidance, and potential XP-8121 development progress could support a rerating.

Bear Case

Drivers

Scannable catalysts and supporting factors

Recent officer open-market sales
XP-8121 Phase 3 initiation
KEVEYIS intellectual-property durability

Scenarios

Bull Target (Scenario probability)

$13 / p=25% prob

Base Target (Scenario probability)

$10 / p=50% prob

Bear Target (Scenario probability)

$7 / p=25% prob

Analysis 2026-09-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.65

Social Sentiment (7d)

0.50

Events

Other notable items detected

EVENT2026-12-31
H2 Recorlev execution and FY2026 guidance delivery
Q2 total revenue reached $92.1 million, net product revenue grew 34% year over year, and Recorlev revenue grew 81%. Management tightened FY2026 total revenue guidance to $385–$390 million [#SEC-8K-2026-08-06].
Prob 72.00% • Move 12.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

Recent officer open-market sales
2026-09-15
Recent Form 4 filings show open-market sales by officers near $8.01–$8.49. This is a potential sentiment overhang, not evidence about operating performance [#SEC-FORM4-2026-09-01].
Prob 55% • Move -5% • Priced-in 50%

Long-term Catalysts

Months to a year

XP-8121 Phase 3 initiation
2026-12-31
Management identified anticipated Phase 3 initiation for XP-8121 later in 2026 as a potential value-creation milestone; timing or execution slippage would weaken the pipeline thesis [#SEC-8K-2026-05-07].
Prob 58% • Move 18% • Priced-in 35%
KEVEYIS intellectual-property durability
2027-09-02
Xeris reported a USPTO Notice of Allowance for a new KEVEYIS patent expected to extend protection through at least 2039. Issuance timing was not disclosed [#SEC-8K-2026-08-06].
Prob 65% • Move 8% • Priced-in 50%

Risks

Gvoke revenue declined 4% year over year in Q2 2026.
Higher commercial and R&D spending could pressure earnings and cash generation.
Low analyst coverage, unavailable revision data, and loose peer comparability reduce conviction.
Recent officer open-market sales may weigh on near-term sentiment but are not an operating signal.
Recorlev concentration and dependence on continued patient-demand growth.
The KEVEYIS patent is at Notice of Allowance stage; issuance timing and final protection are not assured.
XP-8121 Phase 3 initiation timing, development, and funding risk.

Peers

Symbol	Summary
ABSI	Same-sector and similar-market-cap candidate, but the packet provides no operating-comparability evidence; use only as loose biotech risk-appetite context.
MAZE	Similar-market-cap biopharma candidate, but direct comparability with Xeris’s marketed-product portfolio is not established.
TRAX	Similar-market-cap sector candidate; insufficient evidence to anchor valuation against Xeris.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-02

Loading AI feed…

Symbol

Summary

ABSI

Same-sector and similar-market-cap candidate, but the packet provides no operating-comparability evidence; use only as loose biotech risk-appetite context.

MAZE

Similar-market-cap biopharma candidate, but direct comparability with Xeris’s marketed-product portfolio is not established.

TRAX

Similar-market-cap sector candidate; insufficient evidence to anchor valuation against Xeris.